Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895677 | 0.87 | RAB9A (0.72) | NPC1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL28009793 | 0.86 | ALDH1A1 (0.66) | NPC1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL7326778 | 0.85 | RAB9A (0.71) | NPC1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL3873495 | 0.85 | ALDH1A1 (0.61) | NPC1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL5089275 | 0.85 | PIK3CA (0.67) | NPC1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL1331652 | 0.84 | RAB9A (0.73) | NPC1RAB9AKMT2AMAPTCRBN | |
| SCHEMBL13271450 | 0.84 | ALDH1A1 (0.60) | NPC1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL209882 | 0.84 | ALDH1A1 (0.71) | KMT2AALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL31283651 | 0.84 | ALDH1A1 (0.71) | KMT2AALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL9211056 | 0.83 | KMT2A (1.00) | NPC1RAB9AKMT2AMAPTCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| WO-2018029604-A1 | C-3 NOVEL TRITERPENONE WITH C-17 REVERSE AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2018-02-15 | — | — | WO | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| US-8314098-B2 | Pyrazolo-pyrimidine compounds | AJINOMOTO CO., INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| EP-0385351-B1 | Nicotinic acid derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO (JP) | 1995-01-11 | — | — | EP | disclosed |
| US-5025012-A | Cardiovascular disorders; antiischemic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-06-18 | — | — | US | disclosed |
| EP-0385351-A1 | Nicotinic acid derivatives and pharmaceutical compositions comprising same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | NPC1 52/4885RAB9A 1091/4885KMT2A 2391/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | NPC1 20/4885RAB9A 701/4885KMT2A 3318/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NPC1 608/4885RAB9A 903/4885KMT2A 1086/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NPC1 529/4885RAB9A 1957/4885KMT2A 602/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | NPC1 2042/4885RAB9A 1323/4885KMT2A 347/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | NPC1 20/4885RAB9A 701/4885KMT2A 3318/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | NPC1 20/4885RAB9A 701/4885KMT2A 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.